ImmunoGen, Inc.
ImmunoGen, Inc. (IMGN): 4 pipeline candidates · ~22 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
22.4 months
D/E 0.46 · 8% dilution
Lead: Approved
4 candidates
N/A
N/A
A transparent, data-derived signal for ImmunoGen, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$605.5M
Quarterly Burn
$87.5M
Runway
22.4 mo
Revenue
$113.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| elahere | Approved |
| imgc936 | Phase 1 |
| imgn151 | Phase 1 |
| pivekimab sunirine | Phase 2 |
Frequently asked questions
How many drug candidates are in ImmunoGen, Inc.'s pipeline?
ImmunoGen, Inc. (IMGN) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ImmunoGen, Inc.'s lead drug candidate?
ImmunoGen, Inc.'s most advanced tracked candidate is elahere (Approved) for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
What is ImmunoGen, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ImmunoGen, Inc. has approximately 22.4 months of cash runway.
Who is the CEO of ImmunoGen, Inc.?
To Be Held is the chief executive officer of ImmunoGen, Inc. (IMGN).
Get the full picture on ImmunoGen, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.